VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012

Sep 17, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-09-13

Reporting Person: Sachdev Amit (SVP, Corp Affairs & Pub Policy)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-09-13	Common Stock	M	18750	$29.25	Acquired	49858	Direct
2012-09-13	Common Stock	M	9531	$32.16	Acquired	59389	Direct
2012-09-13	Common Stock	S	19644	$55.86	Disposed	39745	Direct
2012-09-13	Common Stock	S	18637	$56.50	Disposed	21108	Direct
2012-09-14	Common Stock	M	9531	$32.16	Acquired	30639	Direct
2012-09-14	Common Stock	S	9531	$58.00	Disposed	21108	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-09-13	Employee Stock Option (right to buy)	$29.25	M	18750	Disposed	2017-07-22	Common Stock (18750)	Direct
2012-09-13	Employee Stock Option (right to buy)	$32.16	M	9531	Disposed	2018-07-23	Common Stock (9531)	Direct
2012-09-14	Employee Stock Option (right to buy)	$32.16	M	9531	Disposed	2018-07-23	Common Stock (9531)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	662	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $55.86 (range $55.25 to $56.23).

F3: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $56.50 (range $56.25 to $57.02).

F5: Fully vested.